To explore the effects of antagonist regimen of progesterone and dydrogesterone combined with luteal support therapy by gonadotropin-releasing hormone agonist (GnRH-a) for treating women with fresh-cycle transplantation on their pregnancy outcomes after pregnancy successfully. Methods: 188 women with successfully pregnancy after fresh-cycle transplantation were selected as the research subjects and were divided into observation group and control group according to the different treatment regimens of luteal support. 92 women in the control group were given antagonist regimen of progesterone and dydrogesterone, and 96 women in the observation group were given luteal support therapy by GnRH-α additionally on the basis of the women in the control group. The effect of luteal support treatment, the incidence rate of OHSS during pregnancy, and the adverse drug reactions rate of the women were compared between the two groups. The pregnancy outcomes of the women in the two groups were followed up. Results: There were no significant differences in the rates of bleeding and pregnancy continuation after hemostasis of the women between the two groups (P>0.05). The total incidence of OHSS during pregnancy (8.3%) and the total incidence of adverse reactions (12.5%) of the women in the observation group had no significantly different from those (13.0% and 12.0%) of the women in the control group (P>0.05). There were no significant differences in the rates of early abortion, late abortion, premature birth, live birth, and fetal malformation of the women between the two groups (P>0.05). Conclusion: The combination of luteal support therapy by GnRH-α in the combined with antagonist regimen of progesterone and dydrogesterone of the women with pregnancy after fresh-cycle transplantation can improve their effect of luteal support without increasing the incidence rate of OHSSS, and which has a certain improvement of their pregnancy outcomes.